These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 35124461)

  • 1. Filamin A forms a complex with EphA2 and regulates EphA2 serine 897 phosphorylation and glioblastoma cell proliferation.
    Tamura Y; Nakamizo Y; Watanabe Y; Kimura I; Katoh H
    Biochem Biophys Res Commun; 2022 Mar; 597():64-70. PubMed ID: 35124461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EphA2 is a key effector of the MEK/ERK/RSK pathway regulating glioblastoma cell proliferation.
    Hamaoka Y; Negishi M; Katoh H
    Cell Signal; 2016 Aug; 28(8):937-45. PubMed ID: 27132626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine kinase activity of EphA2 promotes its S897 phosphorylation and glioblastoma cell proliferation.
    Hamaoka Y; Negishi M; Katoh H
    Biochem Biophys Res Commun; 2018 May; 499(4):920-926. PubMed ID: 29626472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cystine/glutamate antiporter xCT is a key regulator of EphA2 S897 phosphorylation under glucose-limited conditions.
    Teramoto K; Katoh H
    Cell Signal; 2019 Oct; 62():109329. PubMed ID: 31152846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein kinase C phosphorylates the EphA2 receptor on serine 892 in the regulatory linker connecting the kinase and SAM domains.
    Gehring MP; Pasquale EB
    Cell Signal; 2020 Sep; 73():109668. PubMed ID: 32413552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein kinase A can block EphA2 receptor-mediated cell repulsion by increasing EphA2 S897 phosphorylation.
    Barquilla A; Lamberto I; Noberini R; Heynen-Genel S; Brill LM; Pasquale EB
    Mol Biol Cell; 2016 Sep; 27(17):2757-70. PubMed ID: 27385333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ephexin4-mediated promotion of cell migration and anoikis resistance is regulated by serine 897 phosphorylation of EphA2.
    Kawai H; Kobayashi M; Hiramoto-Yamaki N; Harada K; Negishi M; Katoh H
    FEBS Open Bio; 2013; 3():78-82. PubMed ID: 23772378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel extracellular Hsp90 mediated co-receptor function for LRP1 regulates EphA2 dependent glioblastoma cell invasion.
    Gopal U; Bohonowych JE; Lema-Tome C; Liu A; Garrett-Mayer E; Wang B; Isaacs JS
    PLoS One; 2011 Mar; 6(3):e17649. PubMed ID: 21408136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Claudin-4 controls the receptor tyrosine kinase EphA2 pro-oncogenic switch through β-catenin.
    Shang X; Lin X; Howell SB
    Cell Commun Signal; 2014 Oct; 12():59. PubMed ID: 25344320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EphA2 as a novel molecular marker and target in glioblastoma multiforme.
    Wykosky J; Gibo DM; Stanton C; Debinski W
    Mol Cancer Res; 2005 Oct; 3(10):541-51. PubMed ID: 16254188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ionizing radiation induces EphA2 S897 phosphorylation in a MEK/ERK/RSK-dependent manner.
    Graves PR; Din SU; Ashamalla M; Ashamalla H; Gilbert TSK; Graves LM
    Int J Radiat Biol; 2017 Sep; 93(9):929-936. PubMed ID: 28705041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model.
    Tandon M; Vemula SV; Sharma A; Ahi YS; Mittal S; Bangari DS; Mittal SK
    J Gene Med; 2012 Feb; 14(2):77-89. PubMed ID: 22228563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of EPHA2-ROBO1 Heterodimer by SLIT2 Attenuates Non-canonical Signaling and Proliferation in Squamous Cell Carcinomas.
    Srivastava S; Pang KM; Iida M; Nelson MS; Liu J; Nam A; Wang J; Mambetsariev I; Pillai R; Mohanty A; McDaniel N; Behal A; Kulkarni P; Wheeler DL; Salgia R
    iScience; 2020 Nov; 23(11):101692. PubMed ID: 33196021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EphrinA1-EphA2 signal induces compaction and polarization of Madin-Darby canine kidney cells by inactivating Ezrin through negative regulation of RhoA.
    Wakayama Y; Miura K; Sabe H; Mochizuki N
    J Biol Chem; 2011 Dec; 286(51):44243-44253. PubMed ID: 21979959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EphA2 receptor is a key player in the metastatic onset of Ewing sarcoma.
    Garcia-Monclús S; López-Alemany R; Almacellas-Rabaiget O; Herrero-Martín D; Huertas-Martinez J; Lagares-Tena L; Alba-Pavón P; Hontecillas-Prieto L; Mora J; de Álava E; Rello-Varona S; Giangrande PH; Tirado OM
    Int J Cancer; 2018 Sep; 143(5):1188-1201. PubMed ID: 29582409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EphrinA1 repulsive response is regulated by an EphA2 tyrosine phosphatase.
    Parri M; Buricchi F; Taddei ML; Giannoni E; Raugei G; Ramponi G; Chiarugi P
    J Biol Chem; 2005 Oct; 280(40):34008-18. PubMed ID: 16051609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HGF-induced serine 897 phosphorylation of EphA2 regulates epithelial morphogenesis of MDCK cells in 3D culture.
    Harada K; Negishi M; Katoh H
    J Cell Sci; 2015 May; 128(10):1912-21. PubMed ID: 25908849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor.
    Wykosky J; Palma E; Gibo DM; Ringler S; Turner CP; Debinski W
    Oncogene; 2008 Dec; 27(58):7260-73. PubMed ID: 18794797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1.
    Noblitt LW; Bangari DS; Shukla S; Knapp DW; Mohammed S; Kinch MS; Mittal SK
    Cancer Gene Ther; 2004 Nov; 11(11):757-66. PubMed ID: 15359289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphorylation of EphA2 receptor and vasculogenic mimicry is an indicator of poor prognosis in invasive carcinoma of the breast.
    Mitra D; Bhattacharyya S; Alam N; Sen S; Mitra S; Mandal S; Vignesh S; Majumder B; Murmu N
    Breast Cancer Res Treat; 2020 Jan; 179(2):359-370. PubMed ID: 31686261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.